Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Capital Leases (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Capital Leases for 8 consecutive years, with $1.2 million as the latest value for Q1 2026.

  • For Q1 2026, Capital Leases fell 39.68% year-over-year to $1.2 million; the TTM value through Mar 2026 reached $1.2 million, down 39.68%, while the annual FY2025 figure was $1.5 million, 34.32% down from the prior year.
  • Capital Leases hit $1.2 million in Q1 2026 for Kymera Therapeutics, down from $1.5 million in the prior quarter.
  • Across five years, Capital Leases topped out at $2.2 million in Q4 2024 and bottomed at $643000.0 in Q3 2023.
  • Average Capital Leases over 5 years is $1.3 million, with a median of $1.2 million recorded in 2024.
  • Year-over-year, Capital Leases tumbled 48.78% in 2022 and then surged 171.23% in 2024.
  • Kymera Therapeutics' Capital Leases stood at $1.2 million in 2022, then increased by 4.41% to $1.3 million in 2023, then skyrocketed by 71.1% to $2.2 million in 2024, then crashed by 34.32% to $1.5 million in 2025, then fell by 21.27% to $1.2 million in 2026.
  • According to Business Quant data, Capital Leases over the past three periods came in at $1.2 million, $1.5 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.